Role of Facial N Decompression in Unresolved Bells Palsy: Surgical Outcome

2017 ◽  
Vol 5 ◽  
pp. 22-26
Author(s):  
H. Vijayendra ◽  
◽  
Anil Dash ◽  
Sangeetha Ramdass ◽  
V. Kumar ◽  
...  
Keyword(s):  
2020 ◽  
Vol 112 (5) ◽  
pp. S25
Author(s):  
Olubode A. Olufajo ◽  
Delaram J. Taghipour ◽  
Gezzer Ortega ◽  
Cheryl K. Zogg ◽  
Edward E. Cornwell ◽  
...  

2020 ◽  
Vol 112 (5) ◽  
pp. S38
Author(s):  
Olubode A. Olufajo ◽  
Delaram J. Taghipour ◽  
Gezzer Ortega ◽  
Cheryl K. Zogg ◽  
Edward E. Cornwell ◽  
...  

2017 ◽  
Vol 16 (3) ◽  
pp. e1180
Author(s):  
T. Silvestri ◽  
N. Pavan ◽  
G. Chiapparrone ◽  
F. Vedovo ◽  
G. Di Cosmo ◽  
...  

NeuroImage ◽  
1998 ◽  
Vol 7 (4) ◽  
pp. S468
Author(s):  
L. Zamorano ◽  
F.C. Vinas ◽  
A. Matter ◽  
R. Buciuc ◽  
F.G. Diaz

2021 ◽  
Vol 14 ◽  
pp. 117863882110546
Author(s):  
Celine I Partha Sarathi ◽  
Oliver D Mowforth ◽  
Amil Sinha ◽  
Faheem Bhatti ◽  
Aniqah Bhatti ◽  
...  

Introduction: Degenerative cervical myelopathy (DCM) is the commonest cause of adult spinal cord impairment worldwide, encompassing chronic compression of the spinal cord, neurological disability and diminished quality of life. Evidence on the contribution of environmental factors is sparse; in particular, the role of nutrition in DCM is unknown. The objective of this review was to assess the effect of nutrition on DCM susceptibility, severity and surgical outcome. Methods: A systematic review in MEDLINE and Embase was conducted following PRISMA guidelines. Full-text papers in English papers, focussing on cervical myelopathy and nutrition, published before January 2020 were considered eligible. Quality assessments were performed using the GRADE assessment tool. Patient demographics, nutritional factor and DCM outcomes measures were recorded. Relationships between nutritional factors, interventions and disease prognosis were assessed. Results: In total, 5835 papers were identified of which 44 were included in the final analysis. DCM patients with pathological weight pre-operatively were more likely to see poorer improvements post-surgically. These patients experienced poorer physical and mental health improvements from surgery compared to normal weight patients and were more likely to suffer from post-operative complications such as infection, DVT, PE and hospital readmissions. Two trials reporting benefits of nutritional supplements were identified, with 1 suggesting Cerebrolysin to be significant in functional improvement. An unbalanced diet, history of alcohol abuse and malnourishment were associated with poorer post-operative outcome. Conclusion: Although the overall strength of recommendation is low, current evidence suggests nutrition may have a significant role in optimising surgical outcome in DCM patients. Although it may have a role in onset and severity of DCM, this is a preliminary suggestion. Further work needs to be done on how nutrition is defined and measured, however, the beneficial results from studies with nutritional interventions suggest nutrition could be a treatment target in DCM.


2021 ◽  
Vol 420 ◽  
pp. 117240
Author(s):  
Mehdi Chihi ◽  
Oliver Gembruch ◽  
Marvin Darkwah Oppong ◽  
Laurèl Rauschenbach ◽  
Steffen Rauscher ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5034-5034
Author(s):  
Ioana Braicu ◽  
Radoslav Chekerov ◽  
Rolf Richter ◽  
Ignace B. Vergote ◽  
Sven Mahner ◽  
...  

5034 Background: Optimal surgical cytoreduction and response to platinum (P) based chemotherapy (ChTh) remain the cornerstones of therapeutic management of primary EOC. Aim of this study was to analyze the predictive role of HE4 and CA125 as biomarkers (BM) for clinical outcome in primary EOC pts at diagnosis and during subsequent follow-up. Methods: In the European OVCAD project 275 pts with primary EOC were enrolled. Pts were eligible if radical cytoreductive surgery and P-based ChTh were applied. Plasma collected at first diagnosis and 6 months after 1st line ChTh in P-sensitive pts was analyzed for HE4 and CA125 levels using ELISA and Luminex technique, respectively. Results: Complete cytoreduction with no residual tumor disease (RTD) was obtained in 69.9% pts. HE4 and CA125 expression in plasma at first diagnosis correlated with RTD, p = 0.002 and p=0.002, respectively. The sensitivity (SE) and specificity (SP) of the combinative use of both BM in predicting RTD was 64.8% and 73.5%, respectively. Pts having over-expression of both BM in plasma had a 6.1 greater risk for RTD (p<0.001, OR: 6.107, 95% CI 2.41-15.46). P-resistance occurred more frequently when both BM were over-expressed (p=0.028, OR= 3.1, 95%CI 1.13-8.46). Elevated BM levels during follow-up predicted recurrence (SE 90% and SP 71% for CA125 ≥55U/ml; SE 72.7% and SP 81.4% for HE4 ≥150pM) and when HE4 or CA125 were positive, a SE of 86.4% and SP of 72.9% were achieved. Elevated CA125 and HE4 at 6 months following adjuvant therapy was associated with significantly poorer PFS (p<0.001, HR 9.6, 95%CI 3.93-23.44 with elevated HE4 or CA125, and HR=50.52, 95%CI 14.44-176.78, with elevated HE4 and CA125) and OS (p<0.001, HR=7.42 95%CI 1.43-38.42 with elevated HE4 or CA125 and HR=28.38 95%CI 6.50-123.97 with elevated HE4 and CA125). Conclusions: The combinative use of HE4 and CA125 appears to have a significant value in predicting optimal surgical outcome and development of P resistance disease in EOC pts. Elevated plasma levels 6 months after 1st line ChTh significantly correlate with OS and PFS in P-sensitive pts.


2013 ◽  
Vol 30 (3) ◽  
pp. 339-344 ◽  
Author(s):  
Eloísio Alexsandro da Silva ◽  
Tassia Lobountchenko ◽  
Matheus Nemer Marun ◽  
Atila Rondon ◽  
Ronaldo Damião

Sign in / Sign up

Export Citation Format

Share Document